IO Biotech, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing novel, immune-modulating cancer therapies based on our T-win technology platform to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech serves customers in Denmark.

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-08-13)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

IO Biotech Inc (IOBT US)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-08-13)

Current Report (Form 8-K | Period ending 2024-06-06)

Current Report (Form 8-K | Period ending 2024-05-14)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)